N-ACETYL-L-LEUCINE PROTECTS MPTP-TREATED PARKINSON’S DISEASE MOUSE MODELS BY SUPPRESSING DESULFOBACTEROTA VIA THE GUT-BRAIN AXIS

Orally administration of N-acetyl-L-leucine alleviated motor impairments and dopamine neuronal deficits in an animal model of Parkinson’s disease. The findings are consistent with the neuroprotective effects of N-acetyl-L-leucine in several other neurodegenerative disorders.

IntraBio
Privacy Policy Cookies Policy ©2024 IntraBio. All rights reserved.